CO6220856A2 - Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano - Google Patents

Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano

Info

Publication number
CO6220856A2
CO6220856A2 CO09089674A CO09089674A CO6220856A2 CO 6220856 A2 CO6220856 A2 CO 6220856A2 CO 09089674 A CO09089674 A CO 09089674A CO 09089674 A CO09089674 A CO 09089674A CO 6220856 A2 CO6220856 A2 CO 6220856A2
Authority
CO
Colombia
Prior art keywords
crystalline
salt form
crystalline salt
peaks
forms
Prior art date
Application number
CO09089674A
Other languages
English (en)
Spanish (es)
Inventor
Sean Dalziel
Leticia Preza
Pierre-Jean Colson
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39620376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6220856(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CO6220856A2 publication Critical patent/CO6220856A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO09089674A 2007-02-28 2009-08-26 Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano CO6220856A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90409007P 2007-02-28 2007-02-28

Publications (1)

Publication Number Publication Date
CO6220856A2 true CO6220856A2 (es) 2010-11-19

Family

ID=39620376

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09089674A CO6220856A2 (es) 2007-02-28 2009-08-26 Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano

Country Status (26)

Country Link
US (7) US7943772B2 (enExample)
EP (1) EP2132204B1 (enExample)
JP (2) JP5512289B2 (enExample)
KR (1) KR101480530B1 (enExample)
CN (1) CN101616916B (enExample)
AR (2) AR065554A1 (enExample)
AU (1) AU2008219615B2 (enExample)
BR (1) BRPI0807974B8 (enExample)
CA (1) CA2678073C (enExample)
CL (1) CL2008000573A1 (enExample)
CO (1) CO6220856A2 (enExample)
CY (1) CY1115077T1 (enExample)
DK (1) DK2132204T3 (enExample)
ES (1) ES2402031T3 (enExample)
HR (1) HRP20130193T1 (enExample)
IL (1) IL200131A (enExample)
MX (1) MX2009009141A (enExample)
MY (1) MY148318A (enExample)
NZ (1) NZ578871A (enExample)
PL (1) PL2132204T3 (enExample)
PT (1) PT2132204E (enExample)
RU (1) RU2458061C2 (enExample)
SI (1) SI2132204T1 (enExample)
TW (1) TWI409067B (enExample)
WO (1) WO2008106159A1 (enExample)
ZA (1) ZA200905832B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型
TWI415850B (zh) * 2007-07-20 2013-11-21 Theravance Inc 製備mu類鴉片受體拮抗劑之中間物的方法
ES2390195T3 (es) * 2007-08-27 2012-11-07 Theravance, Inc. Compuestos de amidoalquil-8-azabiciclo(3,2,1)octano, como antagonistas del receptor opioide mu
TWI423801B (zh) 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之8-氮雜雙環〔3.2.1〕辛基-2-羥基苯甲醯胺化合物
US7947710B2 (en) * 2007-08-27 2011-05-24 Theravance, Inc. Disubstituted alkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
EP2195313B1 (en) * 2007-08-27 2014-04-02 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2011035142A1 (en) * 2009-09-18 2011-03-24 Adolor Corporation Use of opioid receptor antagonist for gastrointestinal tract disorders
PT3277278T (pt) * 2015-04-02 2020-04-16 Theravance Biopharma R&D Ip Llc Forma farmacêutica de combinação de um antagonista do recetor opioide mu e um agente opioide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5159081A (en) * 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
US6900228B1 (en) * 1998-03-10 2005-05-31 Research Triangle Institute Opiate compounds, methods of making and methods of use
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
TWI244481B (en) * 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US6467084B1 (en) * 1999-12-16 2002-10-15 Emware, Inc. Systems and methods for reprogramming an embedded device with program code using relocatable program code
KR20030009376A (ko) 2000-03-03 2003-01-29 오르토-맥네일 파마슈티칼, 인코퍼레이티드 3-(디아릴메틸렌)-8-아자비사이클로[3.2.1]옥탄 유도체
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GEP20084300B (en) * 2001-10-22 2008-02-11 Pfizer Prod Inc 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
US20040204453A1 (en) * 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
JP3984281B2 (ja) * 2003-04-14 2007-10-03 ファイザー・プロダクツ・インク 3−アザビシクロ〔3,2,1〕オクタン誘導体
CA2522199A1 (en) 2003-04-15 2004-10-28 Pfizer Products Inc. 3-benzhydrylidene-8-aza-bicyclo¬3.2.1|octane derivatives with opioid receptor activity
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1737853A1 (en) 2004-02-03 2007-01-03 Janssen Pharmaceutica N.V. 3-(diheteroarylmethylene)-8-azabicyclo¬3.2.1|octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo¬3.2.1|octane derivatives
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
MX2009004965A (es) 2006-11-07 2009-06-05 Nektar Therapeutics Al Corp Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc 8-氮雜雙環〔3.2.1〕辛烷化合物之結晶型

Also Published As

Publication number Publication date
IL200131A0 (en) 2010-04-15
KR20090115767A (ko) 2009-11-05
US20080207676A1 (en) 2008-08-28
JP5512289B2 (ja) 2014-06-04
WO2008106159A1 (en) 2008-09-04
US8536335B2 (en) 2013-09-17
US20160287572A1 (en) 2016-10-06
PL2132204T3 (pl) 2013-06-28
US10426766B2 (en) 2019-10-01
EP2132204A1 (en) 2009-12-16
BRPI0807974B8 (pt) 2021-05-25
US20150073014A1 (en) 2015-03-12
AU2008219615B2 (en) 2013-05-09
AR109224A2 (es) 2018-11-07
BRPI0807974A2 (pt) 2014-09-16
RU2009135834A (ru) 2011-04-10
US8247555B2 (en) 2012-08-21
DK2132204T3 (da) 2013-04-29
RU2458061C2 (ru) 2012-08-10
TW200845984A (en) 2008-12-01
HRP20130193T1 (hr) 2013-03-31
PT2132204E (pt) 2013-03-25
CN101616916A (zh) 2009-12-30
US20140080856A1 (en) 2014-03-20
TWI409067B (zh) 2013-09-21
US20110184008A1 (en) 2011-07-28
MY148318A (en) 2013-03-29
ZA200905832B (en) 2010-05-26
ES2402031T3 (es) 2013-04-26
SI2132204T1 (sl) 2013-05-31
MX2009009141A (es) 2009-09-03
AR065554A1 (es) 2009-06-17
AU2008219615A1 (en) 2008-09-04
JP2010520198A (ja) 2010-06-10
US7943772B2 (en) 2011-05-17
CY1115077T1 (el) 2016-12-14
NZ578871A (en) 2012-01-12
CA2678073C (en) 2016-01-05
KR101480530B1 (ko) 2015-01-08
IL200131A (en) 2013-03-24
CL2008000573A1 (es) 2008-05-16
JP2013151564A (ja) 2013-08-08
BRPI0807974B1 (pt) 2020-11-24
US8816091B2 (en) 2014-08-26
US20180200246A1 (en) 2018-07-19
CN101616916B (zh) 2011-10-12
US9290491B2 (en) 2016-03-22
US20130072515A1 (en) 2013-03-21
HK1139399A1 (en) 2010-09-17
US9949963B2 (en) 2018-04-24
EP2132204B1 (en) 2013-01-23
CA2678073A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
CO6220856A2 (es) Formas cristalinas de un compuesto de 8-azabiciclo[3,2,1]octano
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
UY29199A1 (es) Derivados tiazol, composiciones que los contienen, procedimientos de preparación y aplicaciones
PE20142353A1 (es) Ansolvatos de sal de noribogaina
CL2008002542A1 (es) Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.
SV2010003567A (es) Derivados bis-(sulfonilamino) en terapia 066
BRPI0720551A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
AR110019A2 (es) Forma cristalina de un compuesto de quinolinona-carboxamida
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
ECSP056134A (es) Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
ECSP066730A (es) Compuestos y procedimientos para uso
ECSP10010346A (es) Compuestos de 3h-[1,2,3]triazolo[4,5-d]pirimidina, su uso como inhibidores de mtor quinasa y pi3 quinasa y su síntesis
BR112013028666A2 (pt) compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7
PE20071220A1 (es) Sales de hidrocloruro de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona y su proceso de preparacion
UY31672A1 (es) &#34;agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación&#34;
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
UY27850A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen
CR20190144A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos
CO2019003894A2 (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
AR053364A1 (es) Compuesto de 1h-imidazo 84,5-c) piridin -2- ilo, composicion farmaceutica que lo comprende, proceso para prepararla y su uso para preparar un medicamento para tratamiento de cancer o artritis
TW200639156A (en) New compounds

Legal Events

Date Code Title Description
FG Application granted